1. Mucosal-associated invariant T cells promote inflammation and intestinal dysbiosis leading to metabolic dysfunction during obesity.
- Author
-
Toubal A, Kiaf B, Beaudoin L, Cagninacci L, Rhimi M, Fruchet B, da Silva J, Corbett AJ, Simoni Y, Lantz O, Rossjohn J, McCluskey J, Lesnik P, Maguin E, and Lehuen A
- Subjects
- Adipose Tissue pathology, Animals, Cytokines genetics, Cytokines metabolism, Diet, High-Fat, Dysbiosis complications, Gastrointestinal Microbiome, Glucose Tolerance Test, Ileum pathology, Inflammation complications, Intestinal Mucosa pathology, Intestines diagnostic imaging, Ligands, Lymphocyte Count, Macrophages metabolism, Magnetic Resonance Imaging, Mice, Mice, Inbred C57BL, Obesity complications, Obesity diagnostic imaging, Phenotype, Pterins pharmacology, Receptors, Antigen, T-Cell metabolism, Dysbiosis immunology, Inflammation pathology, Intestines pathology, Mucosal-Associated Invariant T Cells pathology, Obesity metabolism
- Abstract
Obesity is associated with low-grade chronic inflammation promoting insulin-resistance and diabetes. Gut microbiota dysbiosis is a consequence as well as a driver of obesity and diabetes. Mucosal-associated invariant T cells (MAIT) are innate-like T cells expressing a semi-invariant T cell receptor restricted to the non-classical MHC class I molecule MR1 presenting bacterial ligands. Here we show that during obesity MAIT cells promote inflammation in both adipose tissue and ileum, leading to insulin resistance and impaired glucose and lipid metabolism. MAIT cells act in adipose tissue by inducing M1 macrophage polarization in an MR1-dependent manner and in the gut by inducing microbiota dysbiosis and loss of gut integrity. Both MAIT cell-induced tissue alterations contribute to metabolic dysfunction. Treatment with MAIT cell inhibitory ligand demonstrates its potential as a strategy against inflammation, dysbiosis and metabolic disorders.
- Published
- 2020
- Full Text
- View/download PDF